AMENDMENTS TO THE CLAIMS

The complete listing of all claims will serve to replace all prior versions of the claims. Applicants respectfully request favorable consideration of the present application in light of the present remarks.

Listing of claims

Claims 1-8 (Canceled)

9. (Currently Amended) A ~~P~~pharmaceutical composition[[s]] for oral administration comprising triiodothyronine sulfate at a dose ranging from 5 to 1000 μg together with pharmaceutically acceptable ~~according to any one of claims 7 and or 8, wherein said compositions further comprise~~ additives ~~like~~ such as excipients, diluents, dissolvents, solvents, carriers, dyestuffs, flavouring[[s]] or sweeteners.

10. (Currently Amended) The ~~Pharmaceutical~~ composition[[s]] according to claim [[7]] 9, comprising ~~wherein~~ triiodothyronine sulfate ~~is administered~~ at a dose[[s]] ~~raging~~ ranging from [[5]] 10 to ~~1000~~ 500 μg.

11. (Currently Amended) The ~~Pharmaceutical~~ composition[[s]] according to claim 10, ~~wherein triiodothyronine sulfate is administered at doses raging~~ further comprising from 10 to ~~500~~ 250 μg of thyroxine.

12. (Currently Amended) The ~~Pharmaceutical~~ composition[[s]] according to claim 10, ~~wherein~~ comprising triiodothyronine sulfate ~~is administered~~ at a dose[[s]] ~~raging~~ ranging from 25 to 250 μg.

13. (Currently Amended) The ~~Pharmaceutical~~ composition[[s]] according to claim ~~8,~~ ~~wherein said association is administered at doses ranging~~ 11, further comprising from ~~10 to 500 μg of triiodothyronine sulfate and from 10~~ 25 to ~~250~~ 200 μg of thyroxine.

14. (Currently Amended) A kit comprising (i) a [[P]]pharmaceutical composition[[s]] ~~according to claim 8, wherein said association is administered at doses ranging from 25 to 250~~

~~μg of~~ comprising triiodothyronine sulphate ~~and from 25 to 200 μg of~~ as defined in claim 10 and ((ii) a pharmaceutical composition for oral use comprising an effective amount of thyroxine.

15. (Currently Amended) The [[K]]kit ~~for the differential or sequential administration of the pharmaceutical compositions according to any one of claims 8, 9 and or 11 to 14~~ according to claim 14, comprising from 10 to 500 μg of triiodothyronine sulfate and from 10 to 250 μg of thyroxine, in compositions (i) and (ii), respectively.

16. (Canceled)

17. (New) A method of treating a subject with a pathology due to organic deficiency of triiodothyronine comprising oral administration of triiodothyronine sulfate at a dose ranging from 5 to 1000 μg.

18. (New) The method according to claim 17, wherein the triiodothyronine sulfate is administered at a dose ranging from 10 to 500 μg.

19. (New) The method according to claim 18, wherein the triiodothyronine sulfate is administered at a dose ranging from 25 to 250 μg.

20. (New) A method of treating a subject with a pathology due to organic deficiency of triiodothyronine comprising oral administration of triiodothyronine sulfate in association with thyroxine at doses ranging from 10 to 500 μg and from 10 to 250 μg, respectively.

21. (New) The method according to claim 20, wherein the triiodothyronine sulfate is administered at a dose ranging from 25 to 250 μg and the thyroxine is administered at a dose ranging from 25 to 200 μg.

22. (New) The method according to any one of claims 17 or 20, wherein said pathology is selecetd from the group consisting of original hypothyroidism from autoimmune thyroid affections, hormonal production defects, thyroidectomy, and congenital hypothyroidism.

23. (New) The method according to any one of claims 17 or 20, wherein said pathology is due to reduced activity of type I 5'-iodothyronine monodeiodinase.

24. (New) The method according to claim 23, wherein said reduced activity of type I 5'-iodothyronine monodeiodinase is due to hypothyroidism, non thyroidal systemic illness, fast, or selenium shortage.

25. (New) The kit according to claim 15, comprising from 25 to 250 μg of triiodothyronine sulfate and from 25 to 200 μg of thyroxine, in compositions (i) and (ii), respectively.